Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
LENZ TherapeuticsLENZ +6.15%12 Receivables Turnover is 5.66 as of Mar. 2026. GuruFocus rates LENZ with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 841 Biotechnology companies, LENZ Therapeutics ranks better than 95.96% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. LENZ Therapeutics's Revenue for the
three
months ended in Mar. 2026 was $1.90 Mil. LENZ Therapeutics's average Accounts Receivable for the
three
months ended in Mar. 2026 was $0.34 Mil.
Hence, LENZ Therapeutics's Receivables Turnover for the
three
months ended in Mar. 2026 was 5.66.
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
LENZ Therapeutics Receivables Turnover Related Terms
LENZ Therapeutics Receivables Turnover Historical Data
* Premium members only.
The historical data trend for LENZ Therapeutics's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LENZ vs KRRO, ANTX, OKUR: Receivables Turnover Comparison
For the Biotechnology subindustry, LENZ Therapeutics's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
LENZ Therapeutics Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, LENZ Therapeutics's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where LENZ Therapeutics's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LENZ Therapeutics (LENZ) has a Receivables Turnover of 5.66 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on LENZ Therapeutics and its competitors. According to the industry distribution chart, LENZ Therapeutics ranks #34 out of 841 companies in the Biotechnology industry, placing it in the top 4%.
Is LENZ Therapeutics' Receivables Turnover too high?
LENZ Therapeutics' current Receivables Turnover is 5.66. The Biotechnology industry median Receivables Turnover is 5.29. LENZ Therapeutics' value of 5.66 is 7% above this industry median. Based on the distribution chart, LENZ Therapeutics ranks #34 out of 841 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, LENZ Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does LENZ Therapeutics' Receivables Turnover compare to KRRO and ANTX?
According to the Biotechnology industry distribution chart, LENZ Therapeutics ranks #34 out of 841 companies for Receivables Turnover. This places LENZ Therapeutics in the top 4% of its industry — outperforming the majority of peers. The industry median Receivables Turnover is 5.29. LENZ Therapeutics' value of 5.66 is 7% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.29, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. LENZ Therapeutics's current Receivables Turnover of 5.66 is 7% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on LENZ Therapeutics and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.29 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. LENZ Therapeutics's current Receivables Turnover is 5.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is LENZ Therapeutics stock overvalued right now?
LENZ Therapeutics (LENZ) has a current Receivables Turnover of 5.66. The current Receivables Turnover is 5.66 and 7% above the Biotechnology industry median of 5.29. LENZ Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For LENZ Therapeutics (LENZ), the current Receivables Turnover is 5.66 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
LENZ Therapeutics Inc is a late-stage biopharmaceutical company focused on developing and commercializing therapies to improve vision and developing ophthalmic pharmaceutical products. Its products VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. VIZZ is powered by aceclidine, highlighted by its differentiated mechanism of action as a predominantly pupil-selective miotic that interacts with the iris, with minimal ciliary muscle stimulation.
12GF Score
Get the complete analysis for LENZ
Receivables Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LENZ has been successfully added to your 
